Choueiri TK, et al. - Cabozantinib was evaluated vs sunitinib as initial therapy for advanced renal cell carcinoma (aRCC) of intermediate/poor risk in the randomised phase 2 CABOSUN trial, wherein, improved progression-free survival (PFS) per investigator with cabozantinib was reported. Researchers report PFS by independent radiology review committee (IRC) assessment, objective response rate (ORR) per IRC and updated overall survival (OS) in this study. For cabozantinib vs sunitinib, median PFS per IRC was 8.6 months vs 5.3 months, and ORR per IRC was 20% vs 9%, respectively. Overall, significantly prolonged PFS per IRC was achieved with cabozantinib treatment vs sunitinib as initial systemic therapy for advanced RCC of poor or intermediate risk.